RhoA Silencing Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells

Molecular Cancer Research - United States
doi 10.1158/1541-7786.mcr-08-0251
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Doxorubicin Resistance Induces IL6 Activation in the Colon Cancer Cell Line LS180

Oncology Letters
Cancer ResearchOncology
2018English

Dragon (RGMb) Induces Oxaliplatin Resistance in Colon Cancer Cells

Oncotarget
Oncology
2016English

Annexin A1 Is Involved in Resistance to 5-Fu in Colon Cancer Cells

Oncology Reports
MedicineCancer ResearchOncology
2016English

miR-27b-3p Is Involved in Doxorubicin Resistance of Human Anaplastic Thyroid Cancer Cells via Targeting PPARγ

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2018English

Doxorubicin Resistance in Breast Cancer Cells Is Mediated by Extracellular Matrix Proteins

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Combination of Chemotherapy and Au-Nanoparticle Photothermy in the Visible Light to Tackle Doxorubicin Resistance in Cancer Cells

Scientific Reports
Multidisciplinary
2018English

Enhancement of Doxorubicin Cytotoxicity by Verapamil in Human Breast Cancer Cells

Journal of Pharmaceutical Research International
2019English

MicroRNA-522 Reverses Drug Resistance of Doxorubicin-Induced HT29 Colon Cancer Cell by Targeting ABCB5

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2015English

Sinomenine Sensitizes Multidrug-Resistant Colon Cancer Cells (Caco-2) to Doxorubicin by Downregulation of MDR-1 Expression

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy